ישראל - עברית - Ministry of Health

medici medical ltd, israel - streptococcus pneumoniae - תמיסה להזרקה - streptococcus pneumoniae 25 mcg / 0.5 ml - pneumococcus, purified polysaccharides antigen - pneumococcus, purified polysaccharides antigen - prevention of pneumococcal infections, particularly of the respiratory type, in patients presenting an increased risk over the age of 2 years.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - pneumococcal polysaccharide serotype 1; pneumococcal polysaccharide serotype 14; pneumococcal polysaccharide serotype 18c; pneumococcal polysaccharide serotype 19 f; pneumococcal polysaccharide serotype 19a; pneumococcal polysaccharide serotype 23f; pneumococcal polysaccharide serotype 3; pneumococcal polysaccharide serotype 4; pneumococcal polysaccharide serotype 5; pneumococcal polysaccharide serotype 6a; pneumococcal polysaccharide serotype 6b; pneumococcal polysaccharide serotype 7f; pneumococcal polysaccharide serotype 9v - תרחיף להזרקה - pneumococcal polysaccharide serotype 23f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 19 f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 14 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 9v 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 7f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 6b 4.4 mcg / 0.5 ml; pneumococcal polysaccharide serotype 5 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 4 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 1 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 3 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 6a 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 18c 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 19a 2.2 mcg / 0.5 ml - pneumococcus, purified polysaccharides antigen conjugated - pneumococcus, purified polysaccharides antigen conjugated - active immunisation for the prevention of disease caused by streptococcus pneumoniae serotypes 1,3,4,5,6a, 6b, 7f, 9v, 14,18c,19a,19f, 23f (including sepsis, meningitis, bacteraemia, pneumonia and acute otitis media) in infants and children from 2 months to 5 years of age.in adults 50 years of age and older, prevnar 13 is indicated for: active immunization for the prevention of pneumonia and invasive disease caused by streptococcus pneumoniae serotypes 1, 3, 4, 5, 6a, 6b, 7f, 9v, 14, 18c, 19a, 19f and 23f. this indication is based on immune responses elicited by prevnar 13. there have been no controlled trials in adults demonstrating a decrease in invasive pneumococcal disease or pneumococcal pneumonia after vaccination with prevnar 13.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - tigecycline - אבקה מיובשת בהקפאה לאינפוזיה - tigecycline 50 mg/dose - tigecycline - tigecycline - tygacil is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years of age and older:complicated skin and skin structure infections:complicated skin and skin structure infections caused by escherichia coli, enterococcus faecalis (vancomycin-susceptible isolates ), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus agalactiae, streptococcus anginosus grp. (includes s. anginosus, s. intermedius, and s. constellatus), streptococcus pyogenes, enterobacter cloacae, klebsiella pneumoniae, and bacteroides fragilis .complicated intra-abdominal infections:complicated intra-abdominal infections caused by citrobacter freundii, enterobacter cloacae, escherichia coli, klebsiella oxytoca, klebsiella pneumoniae, enterococcus faecalis (vancomycin-susceptible isolates), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus anginosus grp. (includes s. anginosu

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - tigecycline - אבקה להכנת תמיסה לאינפוזיה - tigecycline 50 mg/dose - tigecycline - tigecycline - tygacil is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years of age and older:complicated skin and skin structure infections:complicated skin and skin structure infections caused by escherichia coli, enterococcus faecalis (vancomycin-susceptible isolates ), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus agalactiae, streptococcus anginosus grp. (includes s. anginosus, s. intermedius, and s. constellatus), streptococcus pyogenes, enterobacter cloacae, klebsiella pneumoniae, and bacteroides fragilis .complicated intra-abdominal infections:complicated intra-abdominal infections caused by citrobacter freundii, enterobacter cloacae, escherichia coli, klebsiella oxytoca, klebsiella pneumoniae, enterococcus faecalis (vancomycin-susceptible isolates), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus anginosus grp. (includes s. anginosu

ישראל - עברית - Ministry of Health

medison pharma ltd - daptomycin 500 mg/vial - lyophilized powder for injection - daptomycin - cubicin (daptomycin for injection) is indicated for the treatment of complicated skin and skin structure infections caused by susceptible strains of the following gram-positive microorganisms: staphylococcus aureus (including methicillin-resistant strains) streptococcus pyogenes streptococcus agalactiae streptococcus dysgalactiae subsp. equisimilis and enterococcus faecalis (vancomycin-susceptible strains only). combination therapy may be clinically indicated if the documented or presumed pathogens include gram-negative or anaerobic organisms. daptomycin is not indicated for the treatment of pneumonia. appropriate specimens for microbiological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to daptomycin. empiric therapy may be initiated while awaiting test results. antimicrobial therapy should be adjusted as needed based upon test results. to reduce the development of drug-resistant bacteria and maintain the effectiveness of cubici

ישראל - עברית - Ministry of Health

allergan israel ltd - gatifloxacin 0.5 %w/v - ophthalmic solution - gatifloxacin - zymaxid is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: aerobic gram- negative bacteria : haemophilus influenzae, aerobic gram-positive bacteria: staphylococcus aureus, staphylococcus epidermidis, streptococcus mitis group*, streptococcus oralis *, streptococcus pneumoniae. efficacy for this organisms was studied in fewer than 10 infections.

ישראל - עברית - Ministry of Health

zoetis israel holding b.v., israel - ceftiofur hydrochloride - תרחיף להזרקה - ceftiofur hydrochloride 50 mg / 1 ml

ישראל - עברית - Ministry of Health

intervet ( israel) ltd - cefquinome as sulfate - תרחיף להזרקה - cefquinome as sulfate 25 mg/ml

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - sulphamethoxazole; trimethoprim - תרחיף - sulphamethoxazole 200 mg / 5 ml; trimethoprim 40 mg / 5 ml - sulfamethoxazole and trimethoprim - sulfamethoxazole and trimethoprim - treatment of urinary tract infections due to susceptible strains of the following organisms: - escherichia coli - klebsiella - enterobacter - proteus mirabilis - proteus vulgaris - proteus morganii. treatment of acute otitis media in children due to susceptible strains of haemophilus influenzae or streptococcus pneumoniae. to date there are limited data available as to the safety of repeated use of resprim in infants under 2 years of age. resprim is not indicated for prophylactic or prolonged administration in otitis media at any age. treatment of acute exacerbations of chronic bronchitis due to susceptible strains of haemophilus influenzae or streptococcus pneumoniae. treatment of enteritis caused by susceptible strains of shigella flexneri and shigella sonnei. resprim is also indicated in the treatment of documented pneumocystis carinii pneumonitis.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - azithromycin - אבקה להכנת תרחיף - azithromycin 2.096 g - azithromycin - azithromycin - zmax is indicated for the treatment of patients 18 years of age and above with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. adults: acute bacterial sinusitis due to haemophilus influenzae moraxella catarrhalis or streptococcus pneumoniae. community-acquired pneumonia due to chlamydophila pneumoniae, haemophilus influenzae mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapy.